The New Drug Special Programme is a science and technology programme that focuses on major strategic products and major industrialisation targets of the country, and carries out integrated and coordinated research within a set time frame. The implementation period is from 2008 to 2020, and is implemented in phases according to the focused development strategy of "paving, combing and highlighting" in the three five-year plans. The overall goal of the new drug program is to develop and technologically transform a number of drugs for 10 types of major diseases, including malignant tumours, to improve the national drug innovation system, to enhance independent innovation capabilities, to accelerate the development of the pharmaceutical industry, and to accelerate the transformation of China's pharmaceutical R&D from generic to innovative and the pharmaceutical industry from a large country to a strong one.

   In 2012, with a tiny scale of 11 people, Shengshi Tai Ke independently undertook the national 12th Five-Year Plan major new drug creation project, so that our research and development of Class I innovative hypoglycemic drugs into the national support track. Through the joint efforts of all our colleagues, we were able to complete the task in excess of our mission and won the praise of the evaluation experts, and concluded the project perfectly. Two patents were granted, one clinical approval was granted and Yu Qiang, the founder and CEO of Centurion, was selected as the subject leader of the National Thousand Talents Program. The new hypoglycemic drug Shengliptin has entered the clinical stage with promising results and continues to receive support from the National 13th Five-Year Plan, led by Mr. Yu's partner, Mr. Ding Torping, Chairman of Shengshi Tai Ke.

Project (subject) task acceptance comments.

The project has exceeded the task target and developed a new dipeptidyl peptidase targeted hypoglycemic drug (Shengliptin phosphate) with independent intellectual property rights, which has obtained relevant clinical approvals and two patent authorisations. It is a new class I chemical drug with good innovation and independent intellectual property rights, and has obtained the relevant clinical approval. The project leader has been selected as one of the Thousand Talents Program, and the team building has been effective. The project has exceeded its target, obtained clinical approval for a new class I chemical drug and two patents, and is recommended to be accepted.